Indeed, therapeutic promise has recently been demonstrated in the ‘jimpy’ mouse model of PMD where single administration of a Plp1 – targeting ASO restored oligodendrocyte numbers, increased myelination, improved motor performance and extended lifespan (Elitt et al., 2020). This evidence concerns the gene PLP1 and Pelizeaus-Merzbacher spectrum disorder.